Biocon gets US FDA nod for its 1st interchangeable biosimilar insulin

Biocon Limited's Semglee insulin has received the US Food and Drug Administration's (FDA) approval as the first biosimilar interchangeable product for treating diabetes. Semglee can therefore be substituted for its reference drug Lantus at pharmacies without a prescription. Biocon said it is "eligible to have exclusivity for 12 months" and "commercial preparations for launch are underway".